Abstract
Castleman’s disease (CD) is a heterogeneous lymphoproliferative disorder of unknown aetiology. Mostly, this disorder is seen in immunocompromised hosts. It is known to be associated with systemic disorders like HIV, HHV-8, lymphoma, and Kaposi sarcoma. As of today, the clinical behaviour and outcome of CD in immunocompetent host remains suboptimally studied. We analyzed consecutively treated cases of CD presented to our centre in last 12 years. Case record files were studied for patient’s characteristics, clinical presentation, baseline laboratory and pathologic parameters, therapy and outcome. This study describes presentation and treatment outcome of CD in immunocompetent patients. Total 16 patients of CD were treated during the study period. The median age of patients at the time of presentation was 40.5 years (range 13–72 years). An equal number of patients (8 each) had unicentric and multicentric CD. Sixty-three percent patients had hyaline vascular subtype while 37 % patients had plasma cell or mixed variant. Majority of the patients had good performance status (ECOG PS 0, 1 in 10 (62.5 %) patients; PS2-4 in 6 (37.5 %) patients). The median duration of symptoms was 6 months (range 2–36 months). None of the patients in our study had associated HIV infection. Six patients presented with fever, out of which four had plasma cell variant of CD and three of them had multicentric involvement. In comparison to unicentric CD, patients with multicentric CD had lower albumin levels (4.15 vs. 3.38 g/dl, p = 0.006), haemoglobin levels (11.3 vs. 9.8, p = 0.06), and lower complete remission rates (62.5 % vs. none). Patients were treated according to the stage and clinical status with surgery, chemotherapy or combination of both modalities. Surgery was the predominant treatment for unicentric CD while multicentric CD was treated with various chemotherapy regimens. Eight patients were treated with chemotherapy (CHOP-based regimen-5, melphalan-prednisolone thalidomide-1, chlorambucil-prednisolone-1, and only corticosteroids-1). In the entire study group, ORR was 72 % (CR 36 %, PR 36 %), one patient died of progressive disease during chemotherapy. Two patients lost to follow-up before assessment of treatment response. Five-year overall survival was 100 and 87 % for unicentric and multicentric CD respectively. Castleman’s disease is a rare lymphoproliferative disorder amongst Indian patients. It more commonly presents as hyaline vascular variant and affects middle-aged individuals. The most remarkable fact in our analysis was a lack of HIV positivity in any of the patient that is in contrast to the majority of the published literature. With multimodality therapy, high response rates and long-term survival were noted in the entire study group.
Similar content being viewed by others
References
Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A (2008) Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev 10(1):25–35
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M et al (2009) The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol Off J Eur Soc Med Oncol ESMO 20(4):775–779
Gessain A, Sudaka A, Brière J, Fouchard N, Nicola MA, Rio B et al (1996) Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman’s disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 87(1):414–416
Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J et al (1991) Interleukin-6 gene expression in Castleman’s disease. Blood 78(11):2923–2930
Reddy D, Mitsuyasu R (2011) HIV-associated multicentric Castleman disease. Curr Opin Oncol 23(5):475–481
Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N et al (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol Off J Am Soc Clin Oncol 25(22):3350–3356
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 45(2):228–247
Luo JM, Li S, Huang H, Cao J, Xu K, Bi YL et al (2015) Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital. BMC Pulm Med 15(1):34
Menke DM, Tiemann M, Camoriano JK, Chang SF, Madan A, Chow M et al (1996) Diagnosis of Castleman’s disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol 105(3):268–276
Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B et al (2011) Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol Off J Am Soc Clin Oncol 29(18):2481–2486
Dong Y, Wang M, Nong L, Wang L, Cen X, Liu W et al (2015) Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 169(6):834–842
Hill AJ, Tirumani SH, Rosenthal MH, Shinagare AB, Carrasco RD, Munshi NC et al (2015) Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol 88(1049):20140670
Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP (2002) Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am 35(7):880–882
Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK (2012) B cell non-Hodgkin’s lymphoma: experience from a tertiary care cancer center. Ann Hematol 91(10):1603–1611
Baghmar S, Mohanti BK, Sharma A, Kumar L, Prakash G, Kumar S et al (2013) Solitary plasmacytoma: 10 years’ experience at All India Institute of Medical Sciences, New Delhi. Leuk Lymphoma 54(8):1665–1670
Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R (2010) Diffuse large B-cell lymphoma: experience from a tertiary care center in North India. Med Oncol Northwood Lond Engl 27(2):310–318
Peterson BA, Frizzera G (1993) Multicentric Castleman’s disease. Semin Oncol 20(6):636–647
Prakash G, Bakhshi S, Raina V, Bhatnagar S, Sharma A, Kumar L et al (2010) Characteristics and pattern of mortality in cancer patients at a tertiary care oncology center: report of 259 cases. Asian Pac J Cancer Prev APJCP 11(6):1755–1759
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There is no potential conflict of interest of authors writing this article.
Research Involving Human Participants and/or Animals
This is a retrospective data analysis and does not involve any human or animal intervention or experiment.
Informed Consent
Informed consent was obtained before data analysis from participating subjects.
Rights and permissions
About this article
Cite this article
Prakash, G., Bal, A., Malhotra, P. et al. Presentation and Outcome of Castleman’s Disease in Immunocompetent Hosts. Indian J Hematol Blood Transfus 32, 468–474 (2016). https://doi.org/10.1007/s12288-015-0602-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-015-0602-6